MedPath

Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer

Phase 3
Completed
Conditions
Thyroid Cancer
Interventions
Drug: Placebo
Registration Number
NCT00704730
Lead Sponsor
Exelixis
Brief Summary

The purpose of this research study is to evaluate the progression-free survival (PFS) with XL184 as compared with placebo (an inactive substance) in subjects with unresectable, locally advanced, or metastatic medullary thyroid cancer (MTC). Subjects will be randomized to receive XL184 or placebo in a 2:1 ratio. XL184 is an investigational drug that inhibits VEGFR2, MET and RET, kinases implicated in tumor formation, growth and migration.

The Clinical Steering Committee for this study, comprised of study doctors who specialize in medullary thyroid cancer, has provided guidance regarding the design of the study. The committee includes: Douglas Ball, MD, Barry Nelkin, PhD, Martin Schlumberger, MD and Steven Sherman, MD.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
330
Inclusion Criteria
  • The subject has a histologically confirmed diagnosis of MTC that cannot be removed by surgery, is locally advanced, or has spread in the body.
  • The subject is at least 18 years old.
  • The subject has an ECOG (Eastern Cooperative Oncology Group) performance status ≤ 2.
  • The subject has documented worsening of disease (progressive disease) at screening compared with a previous CT scan or MRI image done within 14 months of screening.
  • The subject has recovered from clinically significant adverse events (side effects) due to any other medications that were administered prior to randomization.
  • The subject has adequate organ and bone marrow function.
  • Subjects who are sexually active (male and female) must agree to use medically accepted methods of contraception during the course of the study and for 3 months following discontinuation of study treatments.
  • The subject has no other diagnosis of cancer (unless non-melanoma skin cancer, an early form of cervical cancer, or another cancer diagnosed ≥ 2 years previously) and currently has no evidence of malignancy (unless non-melanoma skin cancer or an early form of cervical cancer).
  • Female subjects of childbearing potential must have a negative pregnancy test at screening.
Exclusion Criteria
  • The subject has received prior treatment for their cancer within 4 weeks of randomization (6 weeks for nitrosoureas or mitomycin C).
  • The subject has received radiation to ≥ 25 % of bone marrow.
  • The subject has received treatment with other investigational agents (unapproved therapies) within 4 weeks of randomization.
  • The subject has received treatment with XL184.
  • The subject has brain metastases or spinal cord compression, unless completed radiation therapy ≥ 4 weeks prior to randomization and stable without steroid and without anti-convulsant treatment for ≥ 10 days.
  • The subject has a history of clinically significant episodes of vomiting blood or a recent history of vomiting > 2.5 mL (about 1/2 teaspoon) of red blood.
  • The subject has serious illness other than cancer.
  • The subject is pregnant or breastfeeding.
  • The subject has an active infection requiring ongoing treatment.
  • The subject is incapable of understanding and complying with the protocol or unable to provide informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
1XL184-
2Placebo-
Primary Outcome Measures
NameTimeMethod
Progression-Free Survival (PFS)Treatment period consisted of 4-week cycles with radiologic tumor assessment every 12 weeks from date of randomization until date of first documented PD or date of death from any cause, whichever came first, assessed up to 34 months.

The duration of Progression-Free Survival (PFS) using progression events as determined by Independent Review Committee (IRC) per mRECIST, or death due to any cause. The analysis was conducted after at least 315 subjects were randomized and at least 138 events were observed.

Secondary Outcome Measures
NameTimeMethod
Overall Survival (OS) With XL184 Compared With PlaceboThe pre-specified interim analysis of Overall Survival (OS) was assessed at 44% of required events. Includes data up to 15June2011. As of this date, the number of deaths required to conduct the primary analysis had not been reached.

Duration of Overall Survival (OS) from the time of randomization to death due to any cause. A Kaplan-Meier analysis was performed to estimate the median.

Objective Response Rate (ORR)Assessed at the same time as primary analysis of Progression Free Survival (PFS) data. Assessed at baseline and every 12 weeks until Progressive Disease (PD) up to 34 months.

The proportion of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) as determined by the Independent Review Committee (IRC.) Per Response Evaluation Criteria in Solid Tumor Criteria (mRECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR) disappearance of all target lesions; Partial Response (PR) ≥ 30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) ≥ 20% increase in the sum of the longest diameter of target lesions. Overall Response Rate: ORR=CR +PR

Duration of Objective Response (OR): Independent Radiology Committee (IRC) DeterminedFrom time of first documentation of Objective Response (OR), confirmed at a later visit ≥28 days later as Progressive Disease (PD) as defined by mRECIST or death due to any cause, assessed up to 34 months.

For those subjects with Independent Radiology Committee (IRC) determined Objective Response Rate (ORR), the amount of time from documentation of Objective Response (OR) until Progressive Disease (PD) by mRECIST or death due to any cause.

Biochemical Response Carcinoembryonic Antigen (CEA) %Serum tumor markers CEA evaluated from blood samples collected at screening and every 12 weeks (± 5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.

For each on-treatment tumor marker assessment from each subject, the biochemical response of CEA was determined based on percent increase or decrease from baseline. Best biochemical response over the course of treatment was determined from evaluation of each subject's time point response data. Biochemical response: Complete Response (CR)- Decrease in tumor marker into normal range from baseline value; Partial Response (PR)- Decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD)- No more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD)- Increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE)- Missing baseline value / or baseline value is not elevated and response is not Progressive Disease (PD) / or response can not be determined due to change in assay format.

Biochemical Response Calcitonin (CTN) %Serum tumor markers CTN evaluated from blood samples collected at screening and every 12 weeks (±5 days from randomization) until date of first documented progression or date of death from any cause, whichever came first, assessed for up to 34 months.

For each on-treatment tumor marker assessment from each subject, the biochemical response of CTN was determined based on percent increase or decrease from baseline. Best biochemical response over course of treatment was determined from evaluation of subject's time point response data. Biochemical response criteria: Complete Response (CR) - decrease in tumor marker into normal range from baseline value; Partial Response (PR) - decrease of \>50% from baseline value when baseline value is above normal range; Stable Disease (SD) - no more than a 50% increase and no more than a 50% decrease from baseline value above normal range; Progressive Disease (PD) - increase of \>50% from baseline value when baseline value is above normal range / or increase from low or normal range at baseline to above normal range; Not Evaluable (NE) - missing baseline value / or baseline value is not elevated and response is not PD / or response can not be determined due to change in assay format.

Trial Locations

Locations (49)

Indiana University Melvin and Bren Simon Cancer Center

🇺🇸

Indianapolis, Indiana, United States

Ohio State University, James Cancer Hospital

🇺🇸

Columbus, Ohio, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Hospital of the University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Kansas University Medical Center

🇺🇸

Kansas City, Kansas, United States

CHUM - Hopital Saint-Luc

🇨🇦

Montreal, Quebec, Canada

Universitair Ziekenhuis

🇧🇪

Leuven, Belgium

Washington Cancer Institute

🇺🇸

Washington, District of Columbia, United States

Nebraska Methodist Hospital

🇺🇸

Omaha, Nebraska, United States

Kidwai Institute of Oncology

🇮🇳

Bangalore, India

Hollings Cancer Center

🇺🇸

Charleston, South Carolina, United States

SEAROC Cancer Institute, S.K. Soni Hospital

🇮🇳

Jaipur, India

Central India Cancer Research Institute

🇮🇳

Nagpur, India

Washington University School of Medicine

🇺🇸

Saint Louis, Missouri, United States

Netaji Subhash Chandra Bose Cancer Hospital Research Institute

🇮🇳

Kolkata, India

All India Institute of Medical Sciences

🇮🇳

New Dehli, India

Vermont Cancer Center at Fletcher Allen Health Care

🇺🇸

Burlington, Vermont, United States

Vanderbilt University Medical Center

🇺🇸

Nashville, Tennessee, United States

Stanford Cancer Center

🇺🇸

Stanford, California, United States

University of Colorado Cancer Center

🇺🇸

Aurora, Colorado, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Johns Hopkins University

🇺🇸

Baltimore, Maryland, United States

Peninsula Cancer Institute

🇺🇸

Newport News, Virginia, United States

Gemeinschaftspraxis

🇩🇪

Heidelberg, Germany

Johannes-Gutenberg Universitaet Mainz

🇩🇪

Mainz, Germany

Universitaetsklinikum Tuebingen

🇩🇪

Tuebingen, Germany

Klinikum der Ludwig-Maximilians-Universitaet Muenchen

🇩🇪

Muenchen, Germany

Shatabdi Superspeciality Hospital

🇮🇳

Nashik, India

Deenanath Mangeshkar Hospital & Research Center

🇮🇳

Pune, India

UCLA

🇺🇸

Los Angeles, California, United States

Yale University, School of Medicine

🇺🇸

New Haven, Connecticut, United States

University of Arkansas for Medical Sciences

🇺🇸

Little Rock, Arkansas, United States

University of Alabama at Birmingham, Comprehensive Cancer Center

🇺🇸

Birmingham, Alabama, United States

TGEN Clinical Research Service at Scottsdale Healthcare

🇺🇸

Scottsdale, Arizona, United States

H. Lee Moffet Cancer Center and Research Institute

🇺🇸

Tampa, Florida, United States

University of Iowa

🇺🇸

Iowa City, Iowa, United States

Capitol Comprehensive Cancer Care Clinic and Research Institute

🇺🇸

Jefferson City, Missouri, United States

Henry Ford Health System

🇺🇸

Detroit, Michigan, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Multiple site locations

🇪🇸

Barcelona, Spain

Oregon Health & Science University

🇺🇸

Portland, Oregon, United States

St. Luke's Hospital & Health Network

🇺🇸

Bethlehem, Pennsylvania, United States

Cliniques Universitaires St. Luc

🇧🇪

Brussels, Belgium

Universitaetsklinikum Leipzig

🇩🇪

Leipzig, Germany

Klinik fuer Nuklearmedizin des Universitaetsklinikums Essen

🇩🇪

Essen, Germany

Ludwig-Maximilians-Universitaet Muenchen

🇩🇪

Muenchen, Germany

Universitaetsklinikum Wuerzburg

🇩🇪

Wuerzburg, Germany

Indo-American Cancer Institute and Research Center

🇮🇳

Hyderabad, India

Ruby Hall Clinic

🇮🇳

Pune, India

© Copyright 2025. All Rights Reserved by MedPath